J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief
Recursion Pharmaceuticals has poached Najat Khan from Johnson & Johnson, where she led AI efforts at one of healthcare’s giants.
Khan will serve as chief R&D and commercial officer, along with joining Recursion’s board. The move comes at a critical time for Recursion, as its stock price has fallen 75% since going public in 2021, currently commanding a market capitalization of $1.75 billion. The Utah biotech expects its first Phase 2 readouts later this year for two rare disease drug candidates.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
